Asked by: Apsana Begum (Independent - Poplar and Limehouse)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what criteria the NHS uses to decide whether a child with epilepsy can access a prescription for cannabis medication.
Answered by Edward Argar - Shadow Secretary of State for Justice
Whether to prescribe any medicine is a clinical decision.
The licensed cannabis-based medicine Epidyolex is prescribed and routinely funded on the National Health Service (NHS) for Dravet syndrome and Lennox-Gastaut syndrome (two forms of epilepsy).
However, the latest National Institute for Health and Care Excellence guidelines demonstrate a clear need for more evidence to support routine prescribing and funding decisions for unlicensed cannabis-based products on the NHS.
If an NHS clinician wishes to prescribe these unlicensed products an individual funding request can be made based on whether there is evidence of exceptionality to justify funding the treatment. A request is made for an individual patient whose clinical circumstances are clearly different to other patients with the same condition, and there is a reason why the individual patient would respond differently to other patients and therefore gain more clinical benefit from the proposed treatment.
Asked by: Apsana Begum (Independent - Poplar and Limehouse)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department is making provisions for families who cannot afford to access cannabis medication via private healthcare for children with epilepsy after being refused treatment by the NHS.
Answered by Edward Argar - Shadow Secretary of State for Justice
The Department does not make provision for the funding of medicines outside of the National Health Service (NHS) commissioning systems. NHS funding decisions follow clearly developed procedures that ensure equitable distribution of funding, prioritising those medicines that have proved their safety, quality, and clinical and cost effectiveness.
The licensed cannabis-based medicine Epidyolex is prescribed routinely on the NHS for Dravet syndrome and Lennox-Gastaut syndrome (two forms of epilepsy). The cost of treatments, that have not been assessed for their quality, safety, clinical and cost effectiveness, sought privately, remains the responsibility of patients.